- Home
- LXEH vs ALXO Comparison
LXEH vs ALXO Comparison
Compare LXEH & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LXEH | ALXO |
|---|---|---|
| Founded | 2001 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5M | 68.3M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LXEH | ALXO |
|---|---|---|
| Price | $0.22 | $2.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $3.42 |
| AVG Volume (30 Days) | 709.8K | ★ 872.5K |
| Earning Date | 01-01-0001 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.18 | $0.41 |
| 52 Week High | $50.08 | $2.66 |
Technical Indicators
Market Signals| Indicator | LXEH | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 48.25 | 51.04 |
| Support Level | $0.18 | $2.01 |
| Resistance Level | $0.28 | $2.27 |
| Average True Range (ATR) | 0.03 | 0.23 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 19.20 | 19.23 |
Price Performance
Historical ComparisonAbout LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.